Safety and efficacy of nivolumab in patients with non-small cell lung cancer: An observational study
Latest Information Update: 16 Nov 2017
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Nov 2017 New trial record